Shield and Axis agree pounds 177m biotech merger
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.THE PHARMACEUTICAL industry yesterday witnessed the second Anglo- Scandinavian deal in six weeks when Shield Diagnostics announced a pounds 177m merger with its Norwegian rival, Axis Biochemicals.
The all-share link between the biotechnology groups will create a world leader in the fast-growing market for heart-disease tests, where Shield and Axis had competed fiercely.
The deal - which comes less than two months after the pounds 21bn proposed merger between the British drug giant Zeneca and its Swedish competitor Astra - values Axis at pounds 68m. Although the merger is structured as a one- for-one share swap, the UK group will have to raise up to pounds 20m to meet Norwegian takeover rules requiring companies to pay minority shareholders in cash.
Investors in Shield, the bigger of the two groups, will end up with 62 per cent of the new company, which will have its headquarters in Dundee and its primary listing in London.
The merged group will have a market value of around pounds 177m and sales of pounds 9m, which could skyrocket if its leading products are successful, say analysts.
David Evans, Shield managing director, said the new company would use its scale to increase investment in its core cardiovascular market.
Axis and Shield have created rival versions of an innovative method of predicting heart disease that is cheaper and easier to use than existing tests. Axis's test was launched in early 1998 and is already used by the US drug giant Abbot Diagnostics, while Shield's kit is being launched on to the market. The tests measure the level of a chemical called homocysteine in a patient's blood. A number of studies have shown that high amounts of the substance are linked to heart attacks later in a patient's life.
Mr Evans said the merged company would "dominate" the market for this types of test. Industry experts estimate that the overall market for heart disease prediction is worth over pounds 500m a year.
City analysts welcomed the move, noting that small biotechnology companies needed to restructure to face the increasing buying power of the large pharmaceutical groups. "Shield and Axis have a good fit. The merger will give them more clout to deal with big pharmaceutical companies in licensing deals," said Nick Woolf, senior analyst with BancBoston Robertson Stephens.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments